A Systematic Review of the Effects of Antipsychotics on Anhedonia by Using Knowledge Graph Approach
Authors: 
Xiaoyan Cheng, Hongyun Qin, Jie Yuan, Jie Min, Qianqian Wu, Zhisheng HuangAuthors Info & Claims
Xiaoyan Cheng, Hongyun Qin, Jie Yuan, Jie Min, Qianqian Wu, Zhisheng HuangAuthors Info & ClaimsPages 1212 - 1217
Abstract
Objective: The purpose of the current study is to provides a systematic analysis of the impact of antipsychotic drugs on anhedonia. Methods: We employed the SNOMED CT (Systematized Nomenclature of Medicine - Clinical Terms) and the knowledge graph of brain science, to find relevant concepts associated with anhedonia and antipsychotics usage. Results: Altogether there are 23 relevant publication were included in this comprehensive analysis study. The outcomes suggest that D2 receptor partial agonists, such as caliprazine and aripiprazole, are most effective in alleviating anhedonia. At the same time, the efficacy of antipsychotic drugs in relieving anhedonia is related to childhood abuse, early changes in reward sensitivity and hormones. Conclusions: We can fully understand the impact of antipsychotic drugs on anhedonia by using the Knowledge graph technology. It demonstrated that the Knowledge graph achieves how to structure the disease information and data to be processed, so it can meet the requirements of large-scale computing.
References
[1]
Diagnostic and statistical manual of mental disorders: DSM-5. (American Psychiatric Association, 2013.
[2]
Pelizza, L. & Ferrari, A. Anhedonia in schizophrenia and major depression: state or trait? Ann Gen Psychiatry 8, 22. 2009.
[3]
Herbener, E. S. & Harrow, M. The course of anhedonia during 10 years of schizophrenic illness. J Abnorm Psychol 111, 237–248. 2002.
[4]
Strauss, G. P. & Gold, J. M. A New Perspective on Anhedonia in Schizophrenia. AJP 169, 364–373. 2012.
[5]
Harkness, K. L. The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report. Can J Psychiatry 68, 586–595. 2023.
[6]
Madhukar H., T. & Ella J., D. Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues in Clinical Neuroscience 10, 377–384. 2008.
[7]
Liemburg, E., Aleman, A., Bous, J., Hollander, K. & Knegtering, H. An Open Randomized Pilot Trial on the Differential Effects of Aripiprazole versus Risperidone on Anhedonia and Subjective Well-Being. Pharmacopsychiatry 44, 109–113. 2011.
[8]
Mazza, M., Squillacioti, M. R., Pecora, R. D., Janiri, L. & Bria, P. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. Psychiatry Research 165, 193–196. 2009.
[9]
Németh, G. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet 389, 1103–1113. 2017.
[10]
Rancans, E. The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. International Clinical Psychopharmacology 36, 154–161. 2021.
[11]
Berardis, D. D. Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clin Psychopharmacol Neurosci 19, 174–178. 2021.
[12]
Ragguett, R.-M. & McIntyre, R. S. Cariprazine for the treatment of bipolar depression: a review. Expert Review of Neurotherapeutics 19, 317–323.2019.
[13]
Batinic, B., Ristic, I., Zugic, M. & Baldwin, D. S. Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. Front. Psychiatry 12, 784370. 2021.
[14]
Taylor, D. M. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 57, 49–54. 2003.
[15]
Burris, K. D. Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors. J Pharmacol Exp Ther 302, 381–389.2002.
[16]
Correll, C. U. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69 Suppl 4, 26–36.2008.
[17]
Kiss, B. Cariprazine (RGH-188), a Dopamine D 3 Receptor-Preferring, D 3 /D 2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile. J Pharmacol Exp Ther 333, 328–340. 2010.
[18]
Mailman, R. & Murthy, V. Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity? CPD 16, 488–501. 2010.
[19]
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L. & Schwartz, J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146–151. 1990.
[20]
Huang, M. The Role of Dopamine D 3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens. J Pharmacol Exp Ther 371, 517–525. 2019.
[21]
Laszlovszky, I. P.575 Long-term functional improving effects of cariprazine: post-hoc analyses of acute and predominant negative symptom schizophrenia patient data. European Neuropsychopharmacology 40, S326–S327. 2020.
[22]
Neill, J. C. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. European Neuropsychopharmacology 26, 3–14. 2016.
[23]
Stahl, S. M. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 22, 375–384. 2017.
[24]
Calabrese, F., Tarazi, F. I., Racagni, G. & Riva, M. A. The role of dopamine D 3 receptors in the mechanism of action of cariprazine. CNS Spectr. 25, 343–351. 2020.
[25]
Mandelli, L., Petrelli, C. & Serretti, A. The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression. Eur. psychiatr. 30, 665–680. 2015.
[26]
Vallati, M. Childhood maltreatment and the clinical characteristics of major depressive disorder in adolescence and adulthood. Journal of Abnormal Psychology 129, 469–479. 2020.
[27]
Allen, T. A. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychol. Med. 49, 1629–1638.2019.
[28]
Bijttebier, P., Beck, I., Claes, L. & Vandereycken, W. Gray's Reinforcement Sensitivity Theory as a framework for research on personality–psychopathology associations. Clinical Psychology Review 29, 421–430. 2009.
[29]
Genovese, A., Smith, T., Kramer, H. & Augustyn, M. ‘Is It Her Hormones?’: Psychiatric Diagnoses and Polycystic Ovarian Syndrome. J Dev Behav Pediatr 37, 103–104.2016.
Index Terms
- A Systematic Review of the Effects of Antipsychotics on Anhedonia by Using Knowledge Graph Approach
Recommendations
A Systematic Review: Role of Artificial Intelligence During the COVID-19 Pandemic in the Healthcare System
Certainty, artificial intelligence (AI) has a remarkable role in the control of the COVID-19 pandemic globally. This review article aimed to determine the outcomes/benefits associated with the use of artificial intelligence during the COVID-19 pandemic ...
A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity
AbstractObesity is considered a principal public health concern and ranked as the fifth foremost reason for death globally. Overweight and obesity are one of the main lifestyle illnesses that leads to further health concerns and contributes to ...
Women Infertility: A Systematic Review of Effects and Causes
AbstractRecently, infertility has been affecting a large number of women than men. It is the male or female reproductive system’s disease. Consequently, after 12 months or more of usual insecure sexual intercourse, if they fail to attain pregnancy then ...
Comments
Information & Contributors
Information
Published In
October 2023
1394 pages
ISBN:9798400708138
DOI:10.1145/3644116
Copyright © 2023 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected].
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 05 April 2024
Check for updates
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ISAIMS 2023
ISAIMS 2023: 2023 4th International Symposium on Artificial Intelligence for Medicine Science
October 20 - 22, 2023
Chengdu, China
Acceptance Rates
Overall Acceptance Rate 53 of 112 submissions, 47%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 7Total Downloads
- Downloads (Last 12 months)7
- Downloads (Last 6 weeks)2
Reflects downloads up to 26 Jul 2024
Other Metrics
Citations
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format